Abstract 4247: Racial/ethnic differences in all-cause and cause-specific mortality patterns among a cohort of invasive U.S. breast cancer patients

2018 ◽  
Author(s):  
Alyssa N. Troeschel ◽  
Yuan Liu ◽  
Lindsay Collin ◽  
Kevin Ward ◽  
Keerthi Gogineni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Ethnic Differences ◽  
Breast Cancer Patients ◽  
Specific Mortality ◽  
Racial Ethnic

scholarly journals Breast pain in a diverse population of breast cancer patients

2020 ◽  
Author(s):  
Jami Fukui ◽  
Erin Bantum ◽  
Madison Meister ◽  
Shannon Lim ◽  
Ashley Davidson Marumoto ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Ethnic Differences ◽  
Short Form ◽  
Mcgill Pain Questionnaire ◽  
Diverse Population ◽  
Breast Pain ◽  
Breast Cancer Patients ◽  
Early Stage Disease ◽  
Racial Ethnic

Abstract Background Breast cancer is the most common cancer in women. The majority of women with breast cancer present with early stage disease requiring surgical management. Post-operative breast pain has been reported to be anywhere from 25–60%. Racial disparities in cancer treatment-related symptom burden are known and linked to worse treatment outcomes. There is sparse data regarding racial/ethnic differences in breast pain among breast cancer patients. We evaluated the prevalence of breast pain in breast cancer patients and characterized the pain using a modified short-form McGill pain questionnaire in our diverse population. Methods We performed a cross sectional study, including 237 patients from various outpatient oncology clinics and breast cancer survivorship groups on Oahu and Maui. Participants had the option to complete the survey in person at the clinic or online. Results Eight-four respondents (35.4%) reported breast pain. There were no statistical differences seen in breast pain likelihood according to racial/ethnic group. On multivariate analysis, we did however find significant racial/ethnic differences in the amount of breast pain, where Chinese, Native Hawaiian and Mixed Asian participants reported significantly less pain compared to White participants (1.36, 2.16 and 2.22 vs 2.92, p = < 0.0001, 0.03 and 0.05) on a 10-point pain scale. We found differences in breast pain according to age, chemotherapy, radiation therapy and endocrine therapy use as well as survey location. No differences were seen according to the type of breast or axillary surgery. The most common descriptors of breast pain were sensory compared to affective characteristics. The average self-reported pain score found was 3/10. Overall, in women with breast pain, 33.4% reported the breast pain affected their sleep with 16.7% reporting it affected their work and 15.4% reporting it affected their sexual activity. Conclusions Breast pain is a significant problem in our breast cancer community. This survey assessment has informed our understanding of breast pain in our diverse population. In turn we are developing culturally appropriate pain management strategies to treat this challenging symptom common in breast cancer survivors.

scholarly journals 112P Ethnic differences in presentation of breast cancer patients treated in Hospital Kuala Lumpur, Malaysia

2015 ◽  
Vol 26 ◽  
pp. ix16
Author(s):  
A. Deniel ◽  
N.A. Hakim ◽  
N.A. Md Nordin ◽  
T.M.I. Tg Abu Bakar Sidik ◽  
S. Subramanian ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Ethnic Differences ◽  
Breast Cancer Patients ◽  
Kuala Lumpur

scholarly journals What mediates the racial/ethnic disparity in psychosocial stress among breast cancer patients?

2021 ◽  
Author(s):  
C. T. Sánchez-Díaz ◽  
S. Strayhorn ◽  
S. Tejeda ◽  
G. Vijayasiri ◽  
G. H. Rauscher ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Social Support ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Psychosocial Stress ◽  
Breast Cancer Diagnosis ◽  
Support Needs ◽  
Breast Cancer Patients ◽  
Hispanic Patients ◽  
Racial Ethnic

Abstract Background Prior studies have observed greater levels of psychosocial stress (PSS) among non-Hispanic (nH) African American and Hispanic women when compared to nH White patients after a breast cancer diagnosis. We aimed to determine the independent and interdependent roles of socioeconomic position (SEP) and unmet support in the racial disparity in PSS among breast cancer patients. Methods Participants were recruited from the Breast Cancer Care in Chicago study (n = 989). For all recently diagnosed breast cancer patients, aged 25–79, income, education, and tract-level disadvantage and affluence were summed to create a standardized socioeconomic position (SEP) score. Three measures of PSS related to loneliness, perceived stress, and psychological consequences of a breast cancer diagnosis were defined based on previously validated scales. Five domains of unmet social support needs (emotional, spiritual, informational, financial, and practical) were defined from interviews. We conducted path models in MPlus to estimate the extent to which PSS disparities were mediated by SEP and unmet social support needs. Results Black and Hispanic patients reported greater PSS compared to white patients and greater unmet social support needs (p = 0.001 for all domains). Virtually all of the disparity in PSS could be explained by SEP. A substantial portion of the mediating influence of SEP was further transmitted by unmet financial and practical needs among Black patients and by unmet emotional needs for Hispanic patients. Conclusions SEP appeared to be a root cause of the racial/ethnic disparities in PSS within our sample. Our findings further suggest that different interventions may be necessary to alleviate the burden of SEP for nH AA (i.e., more financial support) and Hispanic patients (i.e., more emotional support).

Trends in germline genetic testing and results into survivorship for women diagnosed with breast cancer or ovarian cancer, 2013 to 2017.

2020 ◽  
Vol 38 (29_suppl) ◽  
pp. 273-273
Author(s):  
Steven J. Katz ◽  
Monica Morrow ◽  
Allison W. Kurian
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Genetic Testing ◽  
Cancer Patients ◽  
Ethnic Minorities ◽  
Test Results ◽  
Breast Cancer Patients ◽  
Level Of Evidence ◽  
Number Of Genes ◽  
Racial Ethnic

273 Background: Genetic testing is increasingly central to breast and ovarian cancer prevention and treatment. Yet, little is known about trends and disparities in receipt of testing and test results after diagnosis. Methods: We linked all female patients with breast or ovarian cancer diagnosed from 2013-2017 in Georgia and California and reported to SEER registries to genetic testing results from four laboratories (Ambry Genetics, GeneDx, Invitae, Myriad Genetics). We combined test results from all labs with SEER data. We classified a test as a multigene panel (MGP) if it included other genes in addition to BRCA1/2. We grouped pathogenic variants (PVs) by level of evidence that supported clinical testing: BRCA1/2; other genes associated with well-established syndromes (syndromic genes); genes whose cancer association is less certain (emerging genes); and any other tested genes (other genes). We categorized patients with a variant of unknown significance (VUS) in any gene but no PVs as VUS-only. We examined trends in receipt of testing and test results overall and by race/ethnic groups. Results: One quarter (25.5%) of 198,001 breast cancer patients, and 34.5% of 15,461 ovarian cancer patients had genetic tests. Test rates increased by only 2% annually; while the number of genes tested per patient increased by 28%. The mean number of genes tested rose from 10 to 35 during the study period. In early 2013, 18.3% of testers had a PV or VUS result, which increased to 37.2% in late 2017. The upward trend was largely due to increase in VUS-only findings. The proportion of tested breast cancer patients with any PV increased from 9.1% to 9.9%: PVs in BRCA1/2 decreased from 7.5% to 5.0% (p<.001), while PV yield for the two other clinical categories (syndromic and emerging genes) increased from 1.6% to 4.9% (p<.001). PVs in any of the other 61 genes were very rare (<1%). By contrast, the VUS rate in breast cancer patients increased markedly from 9.6% in 2013 to 26.2% in 2017. The VUS rate was higher in racial/ethnic minorities (41.0% Asian, 36.5%% Black, 28.0% Latinas versus 25.6% non-Hispanic Whites diagnosed in 2017; p<.001). We observed similar findings for patients with ovarian cancer. Conclusions: A large gap persists in testing ovarian cancer patients (35% versus 100% recommended). Testing more genes per patient was associated with a substantial racial/ethnic gap in VUS with little difference in yield on clinically relevant PVs. Testing a limited subset of genes may optimize yield-to-noise of genetic testing, particularly for racial/ethnic minorities.

Adverse consequences of the COVID-19 pandemic on breast cancer stage distribution and breast cancer disparities.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 10555-10555
Author(s):  
Genevieve A. Fasano ◽  
Yalei Chen ◽  
Solange Bayard ◽  
Melissa Davis ◽  
Vivian Bea ◽  
...  
Keyword(s):  
Breast Cancer ◽  
New York ◽  
New York City ◽  
Cancer Patients ◽  
York City ◽  
Cancer Stage ◽  
Breast Cancer Patients ◽  
Stage Distribution ◽  
Race Ethnicity ◽  
Racial Ethnic

10555 Background: The COVID-19 surge in March 2020 resulted in a hiatus placed on screening mammography programs in support of shelter-in-place mandates and diversion of medical resources to pandemic management. The COVID-related economic recession and ongoing social distancing policies continued to influence screening practices after the hiatus was lifted. We evaluated the effect of the hiatus on breast cancer stage distribution on the diverse patient population of a health care system in New York City, the first pandemic epicenter in the United States. Methods: Breast cancer patients diagnosed January 1, 2019 to December 31, 2020 were analyzed, with comparisons of stage distribution and mammography screen-detection for three intervals: Pre-Hiatus, During Hiatus (March 15, 2020 to June 15, 2020), and Post-Hiatus. Results were stratified by African American (AA), White American (WA), Asian (As) and Hispanic/Latina (Hisp) self-reported racial/ethnic identity. Results: A total of 894 patients were identified; of these, 549 WA, 100 AA, 104 As, and 93 Hisp comprised the final race/ethnicity-stratified study population. Overall, 588 patients were diagnosed Pre-Hiatus, 61 During-Hiatus, and 245 Post-Hiatus. Nearly two-thirds (65.5%) of the Pre-Hiatus cases were screen-detected versus 49.2% During-Hiatus and 54.7% Post-Hiatus (p = 0.002). Frequency of tumors diagnosed < 1 cm declined from 41.9% Pre-Hiatus to 31.7% Post-Hiatus (p = 0.035). WA patients were more likely to have screen-detected disease compared to AA in the Pre-Hiatus period (69.1% vs. 56.1%; p = 0.05) but non-significantly more likely to have screen-detected disease compared to As and Hisp patients (66.2% vs. 56.9%; p = 0.08). In the Post-Hiatus period, the frequency of screen-detected disease was highest among WA patients (63.0%) compared to all other racial/ethnic groups (AA; 48.1%, As-33.3%, and Hisp-40%; p = 0.007). Similar patterns were observed for frequency of tumors diagnosed ≤1cm Pre-Hiatus (WA-44.3% vs AA-26%, p = 0.02; and vs. As-41.3%, Hisp-48%; p = 0.09), and Post-Hiatus (WA-37.7% vs. AA-18.2%, As-30.8%, Hisp-23.5%; p = 0.25). Conclusions: The 3-month pandemic-related mammography screening hiatus resulted in a more advanced stage distribution for New York City breast cancer patients, and worsened pre-existing race/ethnicity-associated disparities, especially for AA pts.

Sign in / Sign up

Export Citation Format

Share Document